Published online Jul 9, 2022. doi: 10.5409/wjcp.v11.i4.360
Peer-review started: March 31, 2021
First decision: July 30, 2021
Revised: August 21, 2021
Accepted: May 12, 2022
Article in press: May 12, 2022
Published online: July 9, 2022
Processing time: 462 Days and 4.9 Hours
Patients with Kawasaki disease (KD) may have abnormal lipid profiles that may last for prolonged periods. The reasons underlying the persistence of lipid abnormalities are unclear in patients with KD.
There is a paucity of literature on the role of adipocytokines and their effect on abnormal lipid metabolism in patients with KD.
To estimate the levels of adipocytokines (adiponectin, leptin and resistin) during the convalescent phase of KD.
Serum adiponectin, leptin and resistin levels were estimated by enzyme-linked immunosorbent assay in patients with KD and controls.
The mean age of patients in the study group was 10.15 ± 3 years. Median serum resistin levels in patients with KD (27.77 ng/mL; [IQR: 18.66, 48.90]) were increased compared to controls (21.20 ng/mL; [IQR: 14.80, 27.00]) (P = 0.04). Median serum leptin levels and adiponectin levels in cases and controls were similar. There was no significant correlation between adipocytokines and the lipid profile in patients with KD. There was no significant difference in all 3 adipocytokines between children with CAAs and without CAAs.
Our results suggest that serum adipocytokine levels may impact lipid abnormalities observed during the convalescent phase of KD.
The leads provided by our work should be applied in a larger and preferably multicentric study to confirm these results.